Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Community-Acquired Pneumonia Treatment Guidelines

Introduction to Treatment Guidelines

  • The American Thoracic Society recommends that pneumonia treatment is stratified by severity and setting, with mild community-acquired pneumonia (CAP) requiring oral amoxicillin or macrolides, hospitalized non-severe CAP requiring combination therapy with amoxicillin plus a macrolide, and severe CAP demanding immediate intravenous broad-spectrum β-lactam plus macrolide therapy 1, 2, 3

Treatment by Severity and Setting

  • For mild CAP, the Infectious Diseases Society of America suggests oral amoxicillin as the first-line agent, targeting Streptococcus pneumoniae, the most common pathogen 4
  • Alternative regimens for mild CAP include macrolides (erythromycin, clarithromycin, or azithromycin) or doxycycline for patients with atypical pathogen coverage needs or penicillin allergy 1, 5, 6
  • The European Respiratory Society recommends that treatment duration for uncomplicated pneumonia should be 7 days 4
  • For hospitalized non-severe CAP, the British Thoracic Society suggests combined oral therapy with amoxicillin plus a macrolide (erythromycin or clarithromycin) as preferred 2, 3
  • The American College of Chest Physicians recommends that most hospitalized patients with non-severe pneumonia can be adequately treated with oral antibiotics 3
  • For severe CAP, the Infectious Diseases Society of America recommends immediate parenteral antibiotics upon diagnosis, with the preferred regimen being intravenous combination therapy: broad-spectrum β-lactamase stable antibiotic (co-amoxiclav, cefuroxime, cefotaxime, or ceftriaxone) plus a macrolide (clarithromycin or erythromycin) 1, 2, 3, 4

Pathogen-Specific Therapy

  • For Streptococcus pneumoniae, the Centers for Disease Control and Prevention recommend penicillin G as the drug of choice in the United States 5, 6
  • For Legionella species, the European Respiratory Society suggests levofloxacin or moxifloxacin (most data for levofloxacin), or macrolide (azithromycin preferred) ± rifampicin 1
  • For Mycoplasma pneumoniae or Chlamydophila pneumoniae, the American Thoracic Society recommends macrolide (erythromycin) or doxycycline 200 mg daily 1, 5

Route of Administration and Transition to Oral Therapy

  • The Infectious Diseases Society of America recommends that the oral route is recommended for non-severe pneumonia unless contraindications exist 2, 3
  • The American College of Chest Physicians suggests that patients initially treated with parenteral antibiotics should be switched to oral therapy when clinical improvement occurs and temperature has been normal for 24 hours, with no contraindication to oral route 2, 3, 4

Management of Treatment Failure

  • The British Thoracic Society recommends that if patients fail to improve after 48-72 hours, a careful review by an experienced clinician of clinical history, examination, prescription chart, and all investigation results should be conducted 2, 3, 4
  • The European Respiratory Society suggests ordering further investigations: repeat chest radiograph, CRP, white cell count, and additional microbiological specimens 2, 3, 4

Duration of Therapy

  • The Infectious Diseases Society of America recommends that treatment duration should generally not exceed 8 days in a responding patient 1
  • The Centers for Disease Control and Prevention suggest that uncomplicated S. pneumoniae pneumonia is typically treated for 7-10 days 5, 6, 4

Critical Timing Considerations

  • The American Thoracic Society recommends that antibiotic treatment should be initiated immediately after diagnosis of CAP 1
  • The American College of Chest Physicians suggests that in patients with CAP and sepsis, immediate administration is essential 1

Special Populations

  • The American College of Obstetricians and Gynecologists recommends that for mild pneumonia in pregnancy, oral amoxicillin is first-line 4
  • The Infectious Diseases Society of America suggests that for severe pneumonia in pregnancy, use IV broad-spectrum β-lactamase stable antibiotic (co-amoxiclav, cefuroxime, or ceftriaxone) plus macrolide (clarithromycin or erythromycin) 4

Community-Acquired Pneumonia Treatment

Patient Management

  • The American Thoracic Society recommends amoxicilina 80-100 mg/kg/day in three doses for children under 30 kg with community-acquired pneumonia 7
  • For patients with a known allergy to penicillin, macrolides (erythromycin, clarithromycin, or azithromycin) or doxycycline are alternative treatment options 8
  • The European Respiratory Society suggests that monotherapy with amoxicilina may be suitable for patients not previously treated in the community or admitted for non-clinical reasons 8
  • The use of fluoroquinolones is not recommended as a first-line treatment for community-acquired pneumonia, but may be considered as an alternative for patients who are intolerant to penicillins or macrolides 8
  • The British Thoracic Society recommends levofloxacino as the only fluoroquinolone currently licensed in the UK for the treatment of community-acquired pneumonia 8
  • The American Academy of Pediatrics recommends evaluating the efficacy of treatment after 2-3 days, with the primary criterion being the presence or absence of fever 7
  • The European Society of Clinical Microbiology and Infectious Diseases recommends a treatment duration of 10 days for pneumococcal pneumonia and at least 14 days for atypical pneumonia 7